Group 1 - The second "Jiawei Xiaoyao Wan - Pharmacy Speaker" event, sponsored by Tongrentang Technology Development Co., Ltd., will start on May 8 and aims to enhance the professional skills of pharmacy staff over a five-month competition [1][3] - The event focuses on empowering pharmacy talent development and improving service quality, aligning with the growing consumer health demands in the domestic market [3][5] - The competition will include various stages such as online preliminaries, online rematch, semifinals, and finals, with opportunities for participants to win cash prizes and gifts [7] Group 2 - The event emphasizes "professional enhancement" and "customer attraction," using Tongrentang's flagship product, Jiawei Xiaoyao Wan, to help pharmacy staff understand product characteristics and market trends [5][3] - Participants can win up to 5,000 yuan in cash rewards and additional prizes for outstanding performance, which can also help drive traffic to their stores [7][5] - The competition format includes PK mode, group challenges, practical exercises, and professional skill contests to comprehensively improve pharmacy operations [5][7]

Core Insights - In Q1 2025, Tongrentang Technology Company focused on market demand, enhancing product variety and channel development to stimulate marketing momentum [1] Group 1: Product Strategy - The company emphasized "focusing" on major products, directing promotional resources towards key varieties such as Yao Medicine 300 Years, Ejiao, and children's medicine, creating a clear product structure [1] - Core products like Xihuang Pill, Jingzhi Niuhuang Jiedu Pian, and Liuwuwei Dihuang Wan series have optimized pricing systems and operational strategies, achieving coverage in over 30 provinces [9] Group 2: Marketing Initiatives - The "Flag Planting Action" marketing campaign covered 10 key provinces, conducting 206 events and nearly 1500 terminal promotion activities, successfully enhancing product shelf presence and awareness [9] - The company targeted younger audiences with innovative marketing strategies, such as the "Beijing Tongrentang Super Good Pill" campaign during the JD Super Brand Day, appealing to their health-conscious yet skeptical mindset [11] Group 3: Community Engagement - The company engaged in community education about product knowledge, leveraging events like the Winter Olympics to promote health trends, particularly in Harbin [11][14] - Creative marketing slogans and campaigns, such as the AI-themed short films, resonated with younger demographics, making products like Jingzhi Niuhuang Jiedu Pian and Ejiao popular during the spring health season [12][14]

有關二零二五年一季度財務信息之公告 北京同仁堂科技發展股份有限公司（「本公司」）根據《證券及期貨條例》（香 港法例第571章）第XIVA部及香港聯合交易所有限公司證券上市規則第13.09條 作出本公告。 （股份代號：1666） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部 或任何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 中國，北京 二零二五年四月二十八日 本公司控股股東北京同仁堂股份有限公司將於二零二五年四月三十日在上海證 券交易所公佈其截至二零二五年三月三十一日止三個月未經審計之一季度業 績，該業績包含本公司及其附屬公司（「本集團」）截至二零二五年三月三十一 日止三個月未經審計的財務信息。為保證本公司全體股東公平、及時地知曉本公 司信息，本公司特此公佈以下財務信息：根據中華人民共和國財政部頒佈的《中 華人民共和國企業會計準則》，截至二零二五年三月三十一日止三個月，本集團 未經審計營業收入約人民幣203,542萬元，未經審計營業成本約人民幣113,994萬 元，及未經審計歸屬於母公司所有者的淨利 ...

(a joint stock limited company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） （Stock Code 股份代號：1666） Dear non-registered shareholder(s), 28 April 2025 Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications With reference to the notification letter dated 4 March 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Tong Ren Tang Technologies Co. Ltd. (the "Company") is writing to remind you t ...

(a joint stock limited company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） （Stock Code 股份代號：1666） Dear registered shareholder(s), 28 April 2025 Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications (Note 1) With reference to the notification letter dated 4 March 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Tong Ren Tang Technologies Co. Ltd. (the "Company") is writing to remind ...

Environmental, Social & Governance Report 環境、社會及管治報告 2024 Environmental, Social and Governance Report 環境、社會及管治報告 2024 Content 目錄 | About This Report | | | --- | --- | | 關於本報告 | 2 | | Board Statement | | | 董事會聲明 | 6 | | About Us | | | 關於我們 | 8 | | Brand and Culture | | | 品牌與文化 | 10 | | 2024 Sustainability Achievements | | | 二零二四年可持續發展成果 | 12 | | Overview of ESG Key Performance | | | Indicators (KPIs) | | | ESG關鍵績效概覽 | 13 | | Awards and Honours | | | 榮譽獎項 | 14 | | ESG Management System | | | ESG責任管理 | 16 | | ...

Financial Performance - The company reported a revenue increase of 12% year-over-year, reaching $1.2 billion for the fiscal year 2024[6]. - For the year ended December 31, 2024, the Group's revenue amounted to RMB 7,259,644,000, representing an increase of 7.18% from RMB 6,773,463,000 for the corresponding period of last year[27]. - The net profit for the year was RMB 886,933,000, a decrease of 10.62% from RMB 992,313,000 in the previous year[27]. - Profit attributable to owners of the Company was RMB 521,795,000, down 11.59% from RMB 590,188,000 in 2023[27]. - Earnings per share decreased to RMB 0.41 from RMB 0.46 in 2023[27]. - The gross margin improved to 55%, up from 52% in the previous year, due to cost optimization strategies[6]. - The gross margin for 2024 was 39.64%, down from 42.04% in 2023[22]. - The gross margin for the year ended December 31, 2024, was 39.64%, down from 42.04% in 2023, while the net profit margin decreased to 12.22% from 14.65%[75]. - The Group's total revenue for the year ended December 31, 2024, was RMB 7,259,644,000, an increase from RMB 6,773,463,000 in 2023, representing a growth of approximately 7.2%[107]. User Growth and Market Expansion - User data showed a growth in active users by 15%, totaling 5 million users by the end of 2024[6]. - Market expansion efforts led to a 25% increase in sales in the Southeast Asia region, now accounting for 30% of total sales[6]. - A new partnership with a leading e-commerce platform is projected to boost online sales by 30% in the upcoming year[6]. Product Development and R&D - New product launches contributed to 20% of total revenue, with three major products introduced in Q4 2024[6]. - The company invested $50 million in R&D for new technologies, focusing on enhancing product efficacy and user experience[6]. - The Group's innovative drug Qishen Granules successfully obtained the Notice of Approval for Clinical Trial, enhancing its research and development capabilities[52]. - Research and development expenses for the year ended December 31, 2024, were RMB 84,823,000, accounting for 1.17% of revenue, down from 1.74% in 2023[76]. Strategic Initiatives - The Group adjusted its marketing strategies to enhance consumer experience and broaden sales channels in response to market challenges[30]. - The Group will continue to optimize its strategic management system and marketing reforms as part of the "14th Five-Year Plan" initiatives[42]. - The Group's marketing strategies include the "Glow Campaign" and "Flag-planting Campaign" to enhance market penetration and consumer engagement[46]. - The Group aims to optimize production processes and improve supply security systems to support growth during the 15th Five-Year Plan[97][100]. Financial Position and Liquidity - The current ratio decreased to 3.81 from 4.49 in 2023, indicating a decline in liquidity[22]. - Total assets increased to RMB 14,408,591,000 from RMB 13,507,742,000 in 2023[22]. - The debt to asset ratio rose to 29.45% from 28.55% in 2023, reflecting a slight increase in leverage[22]. - The liquidity ratio as of December 31, 2024, was 3.81, down from 4.49 in 2023, indicating a decrease in financial resources[64]. - Cash and cash equivalents increased to RMB 412,948,800 as of December 31, 2024, from RMB 274,645,800 in 2023[66]. Challenges and Risks - The Group faced significant increases in raw material costs due to supply chain constraints and rising market demand, impacting production costs[45]. - The Group faces major risks including policy risks and operational risks, which may impact business operations and financial performance[146]. - Increasing regulatory standards in pharmaceuticals impose higher requirements on safety and environmental management, leading to potential cost increases[147]. - The Group's production of Chinese patent medicines involves complex processes and strict quality control, with potential risks of sporadic issues affecting reputation and finances[149]. Shareholder Information - As of December 31, 2024, substantial shareholders held a total of 617,129,000 shares, representing 93.46% of the issued shares[141]. - The largest customer, Tong Ren Tang Holdings and its subsidiaries, contributed RMB 2,257,367,000, representing 31.09% of total revenue, up from 23.61% in 2023[119]. - The Group's purchases from the five largest suppliers accounted for 31.24% of total purchases, with the largest supplier contributing 10.47%[119]. Legal and Compliance - The Group is committed to compliance with various laws and regulations, including the Company Law and Good Manufacturing Practice, to mitigate legal risks[156]. - The Group has implemented a strategic deployment for legal compliance and risk management, enhancing its governance and integrity systems[157]. - There were no significant legal risk events or non-compliance issues reported during the year[158].

（於中華人民共和國註冊成立的股份有限公司） （股份代號：1666） 自願公告 簽署戰略合作協議 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 本公告由北京同仁堂科技發展股份有限公司（「本公司」，連同本公司之附屬公司，「本 集團」）之董事會（「董事會」）自願作出，旨在使本公司股東及潛在投資者了解本集 團之最新業務發展。 董事會欣然宣佈，本公司之附屬公司北京同仁堂國藥有限公司（「同仁堂國藥」）與中 免國際有限公司（「中免國際」）簽署了戰略合作協議（「戰略合作協議」）。 一、 戰略合作協議的主要內容 (一)合作目標 同仁堂國藥與中免國際視彼此為重要合作夥伴，將充分發揮各自領域的優勢，通過戰略 合作協議涉及的合作實現共同發展、利益最大化。雙方建立合作機制，實現資源整合， 促進互利共贏。雙方努力創造條件，將最具競爭力的優勢資源投入合作當中，共同致力 於拓展同仁堂國藥的海外市場，重點拓展「一帶一路」沿線國家及東南亞地區。 1 (二)合作內容 1. 在現有海南免 ...

Core Strategy - The company is focusing on its "big product" strategy, reallocating resources to core products that demonstrate strong market potential and clinical value [1][2] - Since the implementation of the "big product" strategy in 2020, the company has identified over 20 high-value traditional Chinese medicine products from nearly 200 options, categorized into various therapeutic series [1] Product Development - The company has selected five core products, including Jingzhi Niuhuang Jiedu Pian and Liuwei Dihuang Wan, and is implementing differentiated marketing strategies to enhance their market share [2] - The "Yuyao 300 Years" series is being positioned as a key component of marketing activities, aiming to strengthen market presence through partnerships with major retail chains [2] Market Expansion - The company plans to cultivate a range of small to medium-sized products that align with market demands, focusing on preventive health interventions [2] - In the non-pharmaceutical sector, the company aims to explore market potential for health products like Ejiao food series and Pi Pa Lu, leveraging existing sales channels for broader market reach [2]

而同仁堂科技深受合作伙伴欢迎，频频打开市场与渠道空白点的"插旗行动"也将在今年推出升级版，活 动将以"成熟市场巩固，空白市场不白"为原则，以京制牛黄解毒片、西黄丸、感冒清热颗粒、六味地黄 丸、加味逍遥丸等核心品种为突破口，进一步拓宽活动的深度和广度，向消费者传递产品信息、健康知 识等，提升品牌形象，促进产品销售。 "营销模式的调整要跟得上市场的变化。"同仁堂科技相关负责人表示，企业将进一步推动营销模式向着 更灵敏的方向转型，以高效的"扁平化"配置为出发点，缩短销售链条，提高流通效率，同时持续优化各 品种的控销效果，加强对产品、价格、渠道、终端和市场的全面掌控，逐步搭建更为良性立体的品种发 展生态，充分释放品牌优势和市场潜力。 为了达到提升"渠道盈利能力"这一目标，同仁堂科技在年初已对战略合作伙伴、终端渠道、电商渠道等 资源进行深度整合，根据不同区域、不同品类、不同渠道精准施策，给予营销资源倾斜。 以终端门店为例，企业发力打造单体旗舰店，出台标准化的管理流程，规范品种经营数量、活动开展、 产品码放等方面要求，并为旗舰门店提供定制促销品、路演活动、落地广告投放等全方位终端支持。据 了解，合作粘性高的旗舰店还将嵌入 ...